These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34260531)

  • 41. QTc Prolongation to Predict Mortality in Patients Admitted with COVID-19 Infection: An Observational Study.
    Sartorio A; Burrei G; Cristin L; Zoncapè M; Carlin M; Tadiello E; Minuz P; Dalbeni A; Romano S
    Curr Vasc Pharmacol; 2024; 22(2):106-121. PubMed ID: 38073101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
    Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.
    El Kadri M; Al Falasi O; Ahmed R; Al Awadhi A; Altaha Z; Hillis A; Panikkaveetil B; Abdalla S; Ansel Benette H; Almubarak A; Saifuddin M; Alattar Y; Oulhaj A; AlKaabi S
    BMJ Open; 2022 Feb; 12(2):e051579. PubMed ID: 35140148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.
    Choi MY; Weber B; Stevens E; Guan H; Ellrodt J; Oakes E; Di Carli M; Tedrow U; Sauer W; Costenbader KH
    Rheumatol Int; 2022 Oct; 42(10):1767-1774. PubMed ID: 35430712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
    Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
    Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
    Choi MJ; Kang M; Shin SY; Noh JY; Cheong HJ; Kim WJ; Jung J; Song JY
    Int J Infect Dis; 2021 Jan; 102():275-281. PubMed ID: 33127507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
    Gunay S; Caliskan S; Sigirli D; Sahin E
    Bratisl Lek Listy; 2020; 121(11):817-821. PubMed ID: 33164544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
    Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
    J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
    Schneider J; Jaenigen B; Wagner D; Rieg S; Hornuss D; Biever PM; Kern WV; Walz G
    PLoS One; 2021; 16(5):e0249760. PubMed ID: 33974624
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COVID-19 and the burning issue of drug interaction: never forget the ECG.
    Sciaccaluga C; Cameli M; Menci D; Mandoli GE; Sisti N; Cameli P; Franchi F; Mondillo S; Valente S
    Postgrad Med J; 2021 Mar; 97(1145):180-184. PubMed ID: 32820084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of hydroxychloroquine and azithromycin on the corrected qt interval in patients with the novel Coronavirus disease 2019.
    Murat B; Akgun H; Akarsu M; Ozmen A; Murat S
    Rev Assoc Med Bras (1992); 2021 Jul; 67(7):979-984. PubMed ID: 34817510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice.
    Choi BJ; Koo Y; Kim TY; Chung WY; Jung YJ; Park JE; Lim HS; Park B; Yoon D
    Sci Rep; 2021 Mar; 11(1):6918. PubMed ID: 33767276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The evaluation of the short-term and long-term hydroxychloroquine therapy on ECG parameters.
    Uyar S; Kök M; Ayan A; Coşkuner MA; Köker G; Koca N
    Medicine (Baltimore); 2024 Aug; 103(32):e39039. PubMed ID: 39121326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
    Sapp JL; Alqarawi W; MacIntyre CJ; Tadros R; Steinberg C; Roberts JD; Laksman Z; Healey JS; Krahn AD
    Can J Cardiol; 2020 Jun; 36(6):948-951. PubMed ID: 32299753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.
    Oscanoa TJ; Vidal X; Kanters JK; Romero-Ortuno R
    Int J Antimicrob Agents; 2020 Dec; 56(6):106212. PubMed ID: 33164789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.
    Ahmadizar F; Soroush N; Ikram MA; Kors JA; Kavousi M; Stricker BH
    Eur J Prev Cardiol; 2022 Feb; 28(17):1875-1882. PubMed ID: 33623975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. QTc Prolongation in COVID-19 Patients Using Chloroquine.
    Becker ML; Snijders D; van Gemeren CW; Kingma HJ; van Lelyveld SFL; Giezen TJ
    Cardiovasc Toxicol; 2021 Apr; 21(4):314-321. PubMed ID: 33387252
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.
    Russo V; Carbone A; Mottola FF; Mocerino R; Verde R; Attena E; Verde N; Di Micco P; Nunziata L; Santelli F; Nigro G; Severino S
    Front Pharmacol; 2020; 11():582348. PubMed ID: 33132915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.